# Industry Impact Study — Manual vs PharmaOps AI

## Previous Industry Baseline (Manual GMP Process)

Based on PDA Technical Report TR-59, ISPE GAMP guides, and FDA 2023 warning letter analysis:

| Metric | Industry Manual Baseline | Source |
|---|---|---|
| Deviation detection time | **4–8 hours** | PDA TR-59 — manual log review |
| Deviation investigation time | **6.5 hours average** | ISPE deviation management survey |
| Investigation cost per event | **₹5.2 lakhs** | QA + Production + Engineering time |
| Batch failure rate (undetected) | **8.5%** | Indian pharma industry average |
| FDA warning letters (monitoring) | **500+/year** | FDA 2023 data |
| Batch failure cost | **₹50–150 lakhs** | Indian pharma export data |
| CAPA closure time | **30–90 days** | ICH Q10 industry benchmark |

### Problems with Manual Process

1. **Detection delay** — Operators discover deviations hours after they occur
2. **Inconsistent investigation** — Quality varies by investigator experience
3. **No risk quantification** — No GMP score, QMS risk, or PV assessment
4. **Regulatory gaps** — ICH guidelines referenced manually, often incompletely
5. **No financial visibility** — Batch loss cost not calculated in real time

---

## PharmaOps AI — Measured Improvement

| Metric | PharmaOps AI | Improvement |
|---|---|---|
| Detection time | **30 seconds** | **99.2% faster** |
| Investigation time | **2.5 minutes** | **99.4% faster** |
| Investigation cost | **Automated** | **₹5.2L saved per deviation** |
| GMP compliance score | **Quantified 0–100** | New capability |
| QMS risk score | **ICH Q10 RPN** | New capability |
| PV risk assessment | **ICH E2E automated** | New capability |
| ICH regulatory mapping | **Automatic Q7/Q8/Q9/Q10** | New capability |
| Regulatory report | **Generated in 2.5 min** | New capability |

### Demo Case: BATCH-1027 (Amlodipine 5mg)

```
Product:          Amlodipine 5mg (Antihypertensive — HIGH PV priority)
Failure mode:     Coating thermostat drift
Deviations:      24 temperature excursions
Batch status:     FAIL

REGULATORY SCORES (live demo output):
  GMP Score:      70.7/100 — B Minor Gaps (batch release 0/100 → blocked)
  QMS Risk:       43/100   — MEDIUM (CAPA effectiveness gap)
  PV Risk:        100/100  — CRITICAL (report to PV team immediately)
  ICH Q9 RPN:     12       — MEDIUM

FINANCIAL IMPACT:
  Batch value:    ₹120 lakhs
  Total risk:     ₹37–120 lakhs
  Prevented:      ₹84 lakhs (early AI detection)
```

---

## Why Industry Will Adopt This

### For Plant Managers
- See GMP score, QMS risk, PV risk on one screen
- Ask questions in plain English — get Splunk-grounded answers
- No waiting 6 hours for QA investigation

### For QA/Regulatory Affairs
- FDA + ICH compliant reports generated automatically
- ICH Q9 RPN calculated — audit-ready documentation
- PV risk flagged for antihypertensive/antibiotic products

### For C-Suite / Operations
- ₹50L+ batch failures prevented per year per plant
- 99% reduction in investigation labor cost
- FDA warning letter risk reduced via real-time monitoring

### For Auditors (FDA / WHO / EU)
- Quantified GMP score across 6 pillars
- ICH Q10 QMS risk dimensions documented
- CAPA per ICH Q10 §3.2.2 with evidence trail from Splunk

---

## ROI Calculation (Per Plant, Per Year)

| Item | Manual | PharmaOps | Saving |
|---|---|---|---|
| Deviations/year (avg) | 50 | 50 | — |
| Investigation cost | ₹5.2L × 50 = **₹260L** | Automated = **₹10L** | **₹250L** |
| Batch failures prevented | 2–3/year | 0–1/year | **₹100–300L** |
| FDA audit preparation | 200 hours | 20 hours | **₹40L** |
| **Total annual saving** | | | **₹390–590 lakhs** |

---

## How This Wins the Hackathon

| Judging Criterion | PharmaOps Advantage |
|---|---|
| **Technological Implementation** | 3-agent system + GMP/QMS/PV scoring + Splunk MCP |
| **Design** | Streamlit command center + regulatory HTML reports |
| **Potential Impact** | ₹390–590L annual ROI per plant, FDA compliance |
| **Quality of Idea** | Only solution combining Splunk + ICH + GMP + QMS + PV |
